Nature Communications (Nov 2022)
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
- Frank Cichocki,
- Ryan Bjordahl,
- Jodie P. Goodridge,
- Sajid Mahmood,
- Svetlana Gaidarova,
- Ramzey Abujarour,
- Zachary B. Davis,
- Aimee Merino,
- Katie Tuininga,
- Hongbo Wang,
- Akhilesh Kumar,
- Brian Groff,
- Alec Witty,
- Greg Bonello,
- Janel Huffman,
- Thomas Dailey,
- Tom T. Lee,
- Karl-Johan Malmberg,
- Bruce Walcheck,
- Uta Höpken,
- Armin Rehm,
- Bahram Valamehr,
- Jeffrey S. Miller
Affiliations
- Frank Cichocki
- University of Minnesota, Department of Medicine
- Ryan Bjordahl
- Fate Therapeutics
- Jodie P. Goodridge
- Fate Therapeutics
- Sajid Mahmood
- Fate Therapeutics
- Svetlana Gaidarova
- Fate Therapeutics
- Ramzey Abujarour
- Fate Therapeutics
- Zachary B. Davis
- University of Minnesota, Department of Medicine
- Aimee Merino
- University of Minnesota, Department of Medicine
- Katie Tuininga
- University of Minnesota, Department of Medicine
- Hongbo Wang
- University of Minnesota, Department of Medicine
- Akhilesh Kumar
- University of Minnesota, Department of Medicine
- Brian Groff
- Fate Therapeutics
- Alec Witty
- Fate Therapeutics
- Greg Bonello
- Fate Therapeutics
- Janel Huffman
- Fate Therapeutics
- Thomas Dailey
- Fate Therapeutics
- Tom T. Lee
- Fate Therapeutics
- Karl-Johan Malmberg
- Oslo University Hospital
- Bruce Walcheck
- University of Minnesota, Department of Veterinary and Biomedical Sciences
- Uta Höpken
- Max-Delbrück-Center for Molecular Medicine, MDC
- Armin Rehm
- Max-Delbrück-Center for Molecular Medicine, MDC
- Bahram Valamehr
- Fate Therapeutics
- Jeffrey S. Miller
- University of Minnesota, Department of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-35127-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
The use of chimeric antigen receptor modified immune cell therapeutics has improved the treatment of a range of tumours. Here the authors explore a dual-target iPSC-derived NK cell product as a potential therapeutic for the treatment of multiple myeloma.
